Hormone Replacement Therapy for Menopause: Updated Evidence on Benefits and Risks in

Does Hormone Therapy Actually Reduce Menopausal Symptoms Like Hot Flashes?

Menopausal vasomotor symptoms — hot flashes, night sweats, and associated sleep disruption — affect an estimated 80% of women during the menopausal transition. For many, these symptoms significantly impair quality of life and can persist for years. Hormone replacement therapy, particularly systemic estrogen therapy, has been shown in multiple Cochrane systematic reviews to be the most effective pharmacological intervention for these symptoms, substantially reducing both their frequency and severity.

Despite its proven efficacy, HRT use declined sharply after the Women's Health Initiative (WHI) study published initial results in 2002, which raised concerns about cardiovascular and breast cancer risks. However, subsequent reanalyses of the WHI data and newer studies have provided a more nuanced picture. The North American Menopause Society (NAMS), the Endocrine Society, and international menopause organizations now agree that for symptomatic women who are under 60 or within 10 years of menopause onset, the benefits of HRT generally outweigh the risks. This so-called "timing hypothesis" has reshaped clinical practice over the past decade.

What Are the Current Risks and Who Should Avoid Hormone Therapy?

The risk profile of hormone therapy depends heavily on the type of hormone used, the route of administration, and the patient's individual health history. Transdermal estrogen (patches, gels) appears to carry a lower risk of blood clots compared to oral formulations, according to observational data. For women with an intact uterus, a progestogen must be added to protect against endometrial hyperplasia, and the type of progestogen chosen may also influence breast cancer risk — with micronized progesterone potentially carrying a lower risk than synthetic progestins, based on data from the E3N French cohort study.

Current guidelines from NAMS and the International Menopause Society recommend against initiating HRT in women over 60 or more than 10 years past menopause, due to increased cardiovascular risk in this group. Women with a personal history of estrogen-receptor-positive breast cancer, venous thromboembolism, or active liver disease are also generally advised against systemic hormone therapy. For these patients, non-hormonal alternatives such as fezolinetant — a neurokinin 3 receptor antagonist approved by the FDA in 2023 — offer a new option for managing vasomotor symptoms without estrogen exposure.

What Non-Hormonal Alternatives Exist for Managing Menopause Symptoms?

For women who cannot or prefer not to use hormone therapy, the treatment landscape has expanded significantly. Fezolinetant (Veozah), approved by the FDA in May 2023, represents the first in a new class of neurokinin 3 (NK3) receptor antagonists specifically designed to target the thermoregulatory mechanism behind hot flashes. Clinical trials demonstrated that fezolinetant reduced moderate-to-severe hot flash frequency by approximately 60% compared to placebo. This mechanism-based approach acts on the hypothalamic KNDy neurons that become hyperactive when estrogen levels decline.

Older non-hormonal options include low-dose paroxetine (the only SSRI with FDA approval for vasomotor symptoms), gabapentin, and clonidine, though these have more modest efficacy and notable side effects. Cognitive behavioral therapy (CBT) has also shown benefit for sleep disruption and mood symptoms associated with menopause, as demonstrated in randomized trials published in The Lancet. Lifestyle modifications including regular exercise, maintaining a healthy weight, and avoiding known triggers such as alcohol and spicy foods can complement pharmacological approaches but are typically insufficient as standalone treatments for moderate-to-severe symptoms.